Sangamo Therapeutics, Inc. (SGMO) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The disclosure item covering unregistered sales of equity securities, use of proceeds, and issuer repurchases is reported as having no description for Sangamo Therapeutics, Inc. This absence suggests that during the period in question, it either conducted no such transactions or none that triggered additional reportable risk under this section.
Overall, Wall Street has a Moderate Buy consensus rating on SGMO stock based on 1 Buy and 1 Hold.
To learn more about Sangamo Therapeutics, Inc.’s risk factors, click here.